LC/MS Analysis of Clenbuterol In Plasma on AstecĀ® CHIROBIOTICĀ® T with Phospholipid Removal using HybridSPEĀ® Phospholipid
MatƩriaux
Application
LC/MS Analysis of Clenbuterol Enantiomers in Plasma on AstecĀ® CHIROBIOTICĀ® T after SPE using HybridSPEĀ®-Phospholipid
application for HPLCColonne analytique
Colonne chirale pour HPLC AstecĀ® CHIROBIOTICĀ® T
5 μm particle size, L Ć I.D. 10 cm Ć 2.1 mmTube ou plaque pour SPE
Ćtalon
CONDITIONS
sample preparation
SPE (Solid Phase Extraction)
sample/matrix
rat plasma spiked with clenbuterol enantiomers at 10 ng/mL
SPE well plate
HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample addition
100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile. Mix by vortexing the HybridSPE-PPT plate briefly.
elution
apply vacuum
column
CHIROBIOTIC T, 10 cm x 2.1 mm I.D., 5 μm particles (12018AST)
mobile phase
10 mM ammonium formate in methanol
flow rate
0.3 mL/min
column temp.
30 Ā°C
detector
ABI 3200 QT; ESI(+), MRM: 184/104 m/z (phospholipids); 277.2/203.1 m/z (clenbuterol)
injection
10 μL
Description
Application
The HybridSPE method provides significant improvement in LC-MS baseline.
Informations lƩgales
Astec is a registered trademark of Merck KGaA, Darmstadt, Germany
CHIROBIOTIC is a registered trademark of Sigma-Aldrich Co. LLC
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany